First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia

Farhad Ravandi, Susan O'Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey Jorgensen, Partow Kebriaei, Richard Champlin, Gautam Borthakur, Jan Burger, Alessandra Ferrajoli, Guillermo Garcia-Manero, William Wierda, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph+ ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyper-CVAD, and high-dose cytarabine and methotrexate. Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely. Thirty-five patients with untreated Ph+ ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94%) achieved complete remission. Two patients died of infections before response assessment. Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions. With a median follow-up of 14 months (range, 4-37 months), the median disease-free survival and median overall survival have not been reached, with an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793.

Original languageEnglish (US)
Pages (from-to)2070-2077
Number of pages8
JournalBlood
Volume116
Issue number12
DOIs
StatePublished - Sep 23 2010
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Chromosomes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chemotherapy
Therapeutics
Combination Drug Therapy
Cytarabine
Vincristine
Prednisone
Methotrexate
Dasatinib
Survival
Pericardial Effusion
Pleural Effusion
Disease-Free Survival
Mouth
Maintenance
Hemorrhage
Safety
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia. / Ravandi, Farhad; O'Brien, Susan; Thomas, Deborah; Faderl, Stefan; Jones, Dan; Garris, Rebecca; Dara, Samuel; Jorgensen, Jeffrey; Kebriaei, Partow; Champlin, Richard; Borthakur, Gautam; Burger, Jan; Ferrajoli, Alessandra; Garcia-Manero, Guillermo; Wierda, William; Cortes, Jorge; Kantarjian, Hagop.

In: Blood, Vol. 116, No. 12, 23.09.2010, p. 2070-2077.

Research output: Contribution to journalArticle

Ravandi, F, O'Brien, S, Thomas, D, Faderl, S, Jones, D, Garris, R, Dara, S, Jorgensen, J, Kebriaei, P, Champlin, R, Borthakur, G, Burger, J, Ferrajoli, A, Garcia-Manero, G, Wierda, W, Cortes, J & Kantarjian, H 2010, 'First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia', Blood, vol. 116, no. 12, pp. 2070-2077. https://doi.org/10.1182/blood-2009-12-261586
Ravandi, Farhad ; O'Brien, Susan ; Thomas, Deborah ; Faderl, Stefan ; Jones, Dan ; Garris, Rebecca ; Dara, Samuel ; Jorgensen, Jeffrey ; Kebriaei, Partow ; Champlin, Richard ; Borthakur, Gautam ; Burger, Jan ; Ferrajoli, Alessandra ; Garcia-Manero, Guillermo ; Wierda, William ; Cortes, Jorge ; Kantarjian, Hagop. / First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia. In: Blood. 2010 ; Vol. 116, No. 12. pp. 2070-2077.
@article{731a5a5d1acc47d380b22ad508be88a4,
title = "First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia",
abstract = "The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph+ ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyper-CVAD, and high-dose cytarabine and methotrexate. Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely. Thirty-five patients with untreated Ph+ ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94{\%}) achieved complete remission. Two patients died of infections before response assessment. Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions. With a median follow-up of 14 months (range, 4-37 months), the median disease-free survival and median overall survival have not been reached, with an estimated 2-year survival of 64{\%}. The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793.",
author = "Farhad Ravandi and Susan O'Brien and Deborah Thomas and Stefan Faderl and Dan Jones and Rebecca Garris and Samuel Dara and Jeffrey Jorgensen and Partow Kebriaei and Richard Champlin and Gautam Borthakur and Jan Burger and Alessandra Ferrajoli and Guillermo Garcia-Manero and William Wierda and Jorge Cortes and Hagop Kantarjian",
year = "2010",
month = "9",
day = "23",
doi = "10.1182/blood-2009-12-261586",
language = "English (US)",
volume = "116",
pages = "2070--2077",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia

AU - Ravandi, Farhad

AU - O'Brien, Susan

AU - Thomas, Deborah

AU - Faderl, Stefan

AU - Jones, Dan

AU - Garris, Rebecca

AU - Dara, Samuel

AU - Jorgensen, Jeffrey

AU - Kebriaei, Partow

AU - Champlin, Richard

AU - Borthakur, Gautam

AU - Burger, Jan

AU - Ferrajoli, Alessandra

AU - Garcia-Manero, Guillermo

AU - Wierda, William

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2010/9/23

Y1 - 2010/9/23

N2 - The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph+ ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyper-CVAD, and high-dose cytarabine and methotrexate. Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely. Thirty-five patients with untreated Ph+ ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94%) achieved complete remission. Two patients died of infections before response assessment. Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions. With a median follow-up of 14 months (range, 4-37 months), the median disease-free survival and median overall survival have not been reached, with an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793.

AB - The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph+ ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyper-CVAD, and high-dose cytarabine and methotrexate. Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely. Thirty-five patients with untreated Ph+ ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94%) achieved complete remission. Two patients died of infections before response assessment. Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions. With a median follow-up of 14 months (range, 4-37 months), the median disease-free survival and median overall survival have not been reached, with an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph+ ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793.

UR - http://www.scopus.com/inward/record.url?scp=77957191745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957191745&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-12-261586

DO - 10.1182/blood-2009-12-261586

M3 - Article

C2 - 20466853

AN - SCOPUS:77957191745

VL - 116

SP - 2070

EP - 2077

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -